{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T11:25:22Z","timestamp":1769426722693,"version":"3.49.0"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,2,28]]},"DOI":"10.1001\/jama.2022.22873","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T16:01:37Z","timestamp":1677600097000},"page":"685","source":"Crossref","is-referenced-by-count":3,"title":["Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis\u2014Reply"],"prefix":"10.1001","volume":"329","author":[{"given":"Keith S.","family":"Kaye","sequence":"first","affiliation":[{"name":"Robert Wood Johnson Medical School, New Brunswick, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Belley","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, St Louis, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Velicitat","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, St Louis, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"13","key":"jlr220112r1","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial.","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"jlr220112r5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac688","article-title":"Breaking down the breakpoints: rationale for the 2022 Clinical and Laboratory Standards Institute revised piperacillin-tazobactam breakpoints against Enterobacterales.","author":"Tamma","journal-title":"Clin Infect Dis"},{"key":"jlr220112r2","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: 32nd Informational Supplement: CLSI M100-S32","author":"Clinical and Laboratory Standards Institute","year":"2022"},{"key":"jlr220112r3","unstructured":"European Committee on Antimicrobial Susceptibility Testing. http:\/\/www.eucast.org"},{"key":"jlr220112r4","unstructured":"Electronic Medicines Compendium. Tazocin 4 g\/0.5 g powder for soluation for infusion. Pfizer. Accessed November 7, 2022. https:\/\/www.medicines.org.uk\/emc\/product\/1267\/smpc"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2801854\/jama_kaye_2023_lr_220112_1676659358.0415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T16:01:41Z","timestamp":1677600101000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2801854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.22873","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}